Pharmaceutical Companies Focus on Low Side-Effect Therapies in Gout Management
Market Overview The global gout therapeutics market was valued at USD 2.78 billion in 2022 and is expected to grow at a CAGR of 8.1% during the forecast period. This significant growth trajectory is driven by the rising prevalence of gout, greater awareness about disease management, and the introduction of advanced pharmaceutical formulations. Gout, a form of inflammatory arthritis caused by elevated uric acid levels, has become a growing health concern due to aging populations, sedentary lifestyles, and increasing obesity rates worldwide. The demand for effective gout medications, including urate-lowering therapies, anti-inflammatory drugs, and enzyme inhibitors, continues to surge. Additionally, the rise in healthcare expenditure and improved diagnostic technologies are supporting earlier and more accurate diagnoses, further propelling the market. This expanding market landscape presents valuable opportunities for stakeholders involved in drug development, diagnost...